HORMONE REPLACEMENT CLINICAL TRIALS NEEDED FOR "DEFINITIVE" BREAST CANCER RISK DATA -- NIH RESPONSE TO NURSES' HEALTH STUDY FOLLOW-UP ON HORMONES
Clinical trials of hormone replacement therapies are needed to achieve "definitive" breast cancer risk data, the National Institutes of Health asserted June 14 in response to publication of follow-up data from the Nurses' Health Study in the June 15 New England Journal of Medicine by Graham Colditz, MD, et. al., Brigham & Women's Hospital and Harvard Medical School.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth